Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice

Figure 4

Y27 treatment promotion of transforming growth factor (TGF)-β1 and interleukin (IL)-10 secretion by purified CD4+CD25+ T regulatory (Treg) cells in MRL/ lpr mice. MRL/lpr mice (10 weeks old) were treated with vehicle control (saline), cyclophosphamide (CYC; 15 mg/kg), or Y27 (10, 20 and 40 mg/kg) for 10 weeks. (n = 4). Results represent mean ± standard error of the mean (SEM). ##P < 0.01 versus MRL/lpr.

Back to article page